Get started
Author

Zandra Karina Klippel

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2020 · Meletios Dimopoulos, Hang Quach, et al. · The Lancet · 428
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2024 · Thierry Facon, Meletios-Athanasios Dimopoulos, et al. · New England Journal of Medicine · 281
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
2019 · Thierry Facon, Jae Hoon Lee, et al. · Blood · 128
PDF
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim
2017 · David C. Dale, Jeffrey Crawford, et al. · Supportive Care in Cancer · 104
PDF
Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies
2016 · Yanli Li, Zandra Klippel, et al. · Supportive Care in Cancer · 50
Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy
2016 · Yanli Li, Zandra Klippel, et al. · Cancer Chemotherapy and Pharmacology · 44
PDF
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
2019 · Saad Z. Usmani, Hang Quach, et al. · Blood · 43
Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC
2014 · Z K Klippel, J Chou, et al. · Gene Therapy · 41
Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)
2017 · Thierry Facon, Jae Hoon Lee, et al. · Clinical Lymphoma Myeloma & Leukemia · 36
Validation of Claims Algorithms for Progression to Metastatic Cancer in Patients with Breast, Non-small Cell Lung, and Colorectal Cancer
2016 · Beth L. Nordstrom, Jason C. Simeone, et al. · Frontiers in Oncology · 36
PDF
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
2020 · Thierry Facon, Ruben Niesvizky, et al. · Blood Advances · 32
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)
2016 · Tamás Pinter, Zandra Klippel, et al. · Clinical Colorectal Cancer · 29
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
2019 · Jatin Shah, Saad Usmani, et al. · Clinical Lymphoma Myeloma & Leukemia · 24
Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)
2015 · Jatin Shah, Ruben Niesvizky, et al. · Blood · 23
Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice
2017 · Yanli Li, Leila Family, et al. · Journal of the National Comprehensive Cancer Network · 19
PDF
Once‐weekly (70 mg/m 2 ) vs twice‐weekly (56 mg/m 2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials
2020 · Philippe Moreau, Keith A. Stewart, et al. · Cancer Medicine · 18
PDF
A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora
2018 · Leila Family, Yanli Li, et al. · Journal of the National Comprehensive Cancer Network · 13
PDF
Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy
2015 · C Phipps, M Linenberger, et al. · Bone Marrow Transplantation · 13
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series
2017 · David H. Vesole, Joshua Richter, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 12
Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia
2018 · Yanli Li, Leila Family, et al. · Cancer Medicine · 10
PDF
Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation
2016 · Andrew J. Cowan, Zandra K. Klippel, et al. · Amyloid · 8
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies
2024 · Paul G. Richardson, Aurore Perrot, et al. · Blood Cancer Journal · 7
PDF
Relationship Between Severity and Duration of Chemotherapy Induced Neutropenia and Risk of Infection Among Patients with Non-Myeloid Malignancies
2014 · Yanli Li, Xiaolong Shih, et al. · Blood · 6
Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.
2025 · Meletios Athanasios Dimopoulos, Xavier P. Leleu, et al. · Journal of Clinical Oncology · 5
PDF
P931: Isatuximab in Relapsed Multiple Myeloma Patients With Ultra-high-risk Cytogenetics: Icaria-mm and Ikema Subgroup Analysis
2023 · Philippe Moreau, Aurore Perrot, et al. · HemaSphere · 3
Works count: 58
Citation count: 1,436
H-index: 16
I10-index: 20
Year
Topic
Type